Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors by Pipe, Steven W. et al.
610  |   wileyonlinelibrary.com/journal/hae Haemophilia. 2019;25:610–615.© 2019 John Wiley & Sons Ltd
1  | BACKGROUND AND OBJEC TIVES FOR 
THE NATIONAL BLUEPRINT FOR FAC TOR 
VII I  INHIBITOR RESE ARCH
As elaborated by Sabatino et al,1 five decades of advances have 
brought us widespread availability of safe and effective haemophilia 
treatment. However, inhibitors, neutralizing alloantibodies to factor 
VIII, still occur in ~25%‐30% of persons with severe haemophilia 
A. Within the US, it is estimated that there are over 1000 individ‐
uals with a factor VIII inhibitor.2 Inhibitors are associated with in‐
creased risk from bleeding and twice the rate of hospitalization for 
a bleeding complication, increased morbidity from joint disease and 
significantly increased rate of death due to bleeding‐related causes 
compared to those without inhibitors. Over the last 30 years, we 
have gained insights on risk factors for inhibitor development from 
retrospective and parallel‐cohort studies as well as meta‐analyses.3 
However, there is still much to be learned about the basic mecha‐
nisms underlying this immune response and few studies that have 
significantly impacted inhibitor prevention and eradication.
In 2017, a multi‐stakeholder summit coordinated by the Centres for 
Disease Control's Division of Blood Disorders (DBD) identified the need 
for a national, coordinated strategy to develop actionable solutions 
to the problem of FVIII inhibitors.4 Several months later, the Medical 
and Scientific Advisory Council (MASAC) to the National Haemophilia 
Foundation formed the MASAC Inhibitor Prevention and Eradication Working 
Group with a mandate to engage the haemophilia community in the devel‐
opment of a national scientific agenda that would ensure the coordinated 
future conduct of the most efficient and impactful research. Discussions 
within this Working Group, which included the Deputy Director of the 
Division of Blood Diseases and Resources, National Heart, Lung, and 
Blood Institute (NHLBI) of the National Institutes of Health (NIH), led to 
the concept for The NHLBI State of the Science (SOS) Workshop entitled 
Factor VIII Inhibitors: Generating a National Blueprint for Future Research held 
on the NIH campus on May 15 and 16, 2018. The goal of this workshop 
was to solicit input from all constituencies within the US haemophilia com‐
munity, as well as international collaborators, into the development of a 
coordinated and collaborative national blueprint for future basic, transla‐
tional, and clinical research focused on factor VIII (FVIII) immunogenicity 
and FVIII inhibitor prevention and eradication. The organizational devel‐
opment of this workshop has been described by Sabatino et al.1
2  | SUMMARY OF WORKING GROUP 
REPORTS
The blueprints for future basic, translational and clinical research in 
FVIII immunogenicity, and in the prevention and eradication of FVIII 
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inhibitors has been detailed in each of the full Working Group re‐
ports.5‐8 This paper will serve to highlight and integrate several key 
points from each body of work.
2.1 | Working Group 1: scientific priorities and 
innovative implementation strategies for FVIII 
inhibitor clinical trials
This Working Group considered innovative approaches to the de‐
sign and implementation of feasible clinical trials for prevention and/
or eradication of FVIII inhibitors, with special consideration of inte‐
gration of novel non‐factor therapeutics and gene therapy into the 
standard of care for FVIII inhibitor patients.5 Two proposed trials in 
these areas served to highlight the incorporation of innovative trial 
design, establishment of a functional clinical trials infrastructure, 
facilitation of international collaboration, support of public‐private 
partnerships, strong patient engagement, and the training of the fu‐
ture workforce, as vital to a robust and well‐coordinated future clini‐
cal trials enterprise in the US. In this vision, clinical trials would be 
integrated into and informed by a national system for data and bio‐
specimen collection,6 and would serve as platforms for mechanistic 
studies of FVIII immunogenicity and the host response.7,8
2.2 | Working Group 2: scientific priorities and 
strategies for 21st century data and specimen 
collection and observational FVIII inhibitor 
cohort studies
This Working Group focused on the following key areas to identify the 
best future state for lifespan observational cohorts.6 This group identi‐
fied an existing haemophilia data/specimen collection infrastructure on 
which to build a nationally integrated and coordinated 21st century data 
and specimen collection network designed to support basic, transla‐
tional and clinical research (clinical trials and observational cohort stud‐
ies). This enhanced data/specimen collection and storage enterprise 
would leverage federally‐funded resources, capitalize on informatics 
and biorepository experience from outside the field, serve to cross‐
train haemophilia experts in data science and epidemiology, as well as 
support training efforts across the haemophilia community, and incor‐
porate several progressive principles in data and biorepository science.
Data acquisition and storage would necessarily meet the NIH FAIR 
(Findable, Accessible, Interoperable, Reusable) guidance9 and encom‐
pass the realms of human subjects, data sharing, ethics, and both 
clinician‐ and patient (participant)‐ entered data collection. Within 
these realms, the group addressed the need for an optimized data 
enterprise to revisit and incorporate policies and procedures related 
to the design of studies and informed consent for long term use of 
data; single institutional review board review of studies; international 
sharing of anonymized data; flexible database architecture; software 
interfaces to facilitate interoperability between clinical and research 
databases; and the consistent use of standard measures and high 
quality patient‐relevant outcome (PRO) elements and instruments for 
both data collection and the definition and analysis of outcomes.
Centrally regulated biospecimens acquisition and storage would 
encompass the capacity to store and efficiently distribute pheno‐
typically‐linked biospecimens to investigators for use in reviewed 
and approved scientific studies; to establish standardized processes 
for on‐site small volume specimen collection, storage and shipment; 
and to coordinate efforts with NHLBI's BioLINCC, an archival data‐
linked biospecimen repository.10
2.3 | Working Group 3: scientific priorities and 
implementation strategies for acquiring an actionable 
understanding of FVIII immunogenicity and the 
immunology of both the host immune 
response and tolerance
This Working Group proposed basic and translational research on 
the immune response to factor VIII that would explore both the 
mechanisms of the initial immune response to FVIII that results in 
peripheral tolerance or inhibitor development, and the mechanisms 
by which the immune system responds to FVIII exposure within im‐
mune tolerance regimens following initial inhibitor development.7 
Three scientific priorities were identified:
1. Activation signals and immune regulation that shape the re‐
sponse to FVIII in humans.
2. Utility of animal models and non‐animal approaches (in silico, ge‐
netic, ‐omics, single cell, and other in vitro) to help predict inhibi‐
tor formation and identify novel therapeutics.
3. Impact of the source of FVIII, its structure, and von Willebrand 
factor (VWF) on immunogenicity and tolerance (including the im‐
pact of gene therapy on FVIII tolerance versus immunogenicity).
Addressing these questions would require that mechanistic studies 
be integrated into clinical antenatal/neonatal and lifespan cohort stud‐
ies and into clinical trials through which biospecimens linked to patient 
phenotype and key clinical events would be collected.5,6,8 As part of 
their proposed implementation plan, this Working Group identified 
the opportunities for emerging workforce training in team science that 
would draw various disciplines, including but not limited to biochemis‐
try, genetics, genomics, bioinformatics, and immunology.
2.4 | Working Group 4: design of pregnancy/birth 
longitudinal cohorts that leverage omics, existing 
phenotypic data, and in silico modelling to study FVIII 
immunogenicity, as well as inhibitor development and 
eradication
This Working Group was asked to consider the design of a preg‐
nancy/birth longitudinal cohort that would leverage ‐omics, 
existing phenotypic data, and in silico modelling to elucidate 
mechanisms of immunogenicity and tolerance to FVIII exposure 
would inform the development of prediction tools for inhibitor 
risk, strategies to avoid modifiable risk factors, and novel inter‐
ventions during the highest risk period.8 Their mandate included 
612  |     PIPE Et al.
the design of data capture and mechanistic studies, based on the 
translational scientific priorities required to build precision (per‐
sonalized) medicine‐based clinical algorithms that can be applied 
across the lifespan.
This group recommended that a longitudinal study beginning in 
the antenatal period with the enrolment of known carriers for severe 
haemophilia A during pregnancy, and continuing with the follow‐up 
of affected offspring through the highest risk period for inhibitor 
development, would offer the first insights into the factors that in‐
fluence inhibitor development prior to the first exposure. Technical 
advances in ‐omics and computational biology, as well as the pre‐
viously unexplored potential contributions of foetal and placental 
biology, would be brought to bear on the study of this unique cohort 
to better understand, predict, and treat haemophilia inhibitor forma‐
tion and understand tolerance. Such a study could be best accom‐
plished through novel interdisciplinary efforts, and through patient 
community engagement to overcome the barriers to enrolment. The 
infrastructure required to support such a cohort and integrate the 
required mechanistic studies were informed by the deliberations of 
Working Groups 2 and 3.6,7
3  | OVERVIE W OF THE INTEGR ATED 
BLUEPRINT FOR FAC TOR VII I  INHIBITOR 
RESE ARCH IN THE US
The overarching theme that emerged from the SOS Workshop was 
the idea of inhibitor investigation over the lifespan (Figure 1). New 
insights on inhibitor development will require holistic research in‐
vestigation that encompasses the antenatal period through perina‐
tal/neonatal transition, and early childhood through late adulthood. 
Research programs would ideally have the following characteristics: 
(a) they would study the entirety of the lifespan and include longitu‐
dinal surveillance and assessment of outcomes on a national scale; 
(b) they would enable subject discovery for observational studies; 
(c) they would facilitate subject discovery from within observational 
cohorts; and (d) they would ideally encompass research into the de‐
velopmental origins of health and disease (DOHaD).
At any point in time, persons with haemophilia can be identified 
within one of three “swim lanes”, or cohorts, based on their history 
of exposure and inhibitor status—those who are at risk for an inhib‐
itor, those who have developed an inhibitor or those who are toler‐
ant to FVIII (Figure 1). The broadest participation would be at the 
registry and biorepository level. Over the course of the lifespan, 
individuals would move between these swim lanes according to 
their FVIII exposure and the evolution of their immune response. 
Regardless of their prior history, individuals may enter the obser‐
vational cohorts into whichever swim lane is consistent with their 
clinical status. For example, newly diagnosed infants may be iden‐
tified de novo or from known carriers and be part of observational 
cohort studies to identify biomarkers for inhibitor development. 
Those subjects with positive biomarkers could be recruited into 
clinical trials for inhibitor prevention. Following clinical trial inter‐
vention, those subjects could return to their observational cohorts 
within their new swim lanes or subsequently be recruited into 
clinical trials for inhibitor eradication. The fluid movement from 
F I G U R E  1   Schematic for inhibitor investigation over the lifespan
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observational cohort to clinical trial participation and back to ob‐
servational cohort with the longitudinal insights from the entirety 
of their clinical phenotyping and personalized ‐omics would be 
particularly powerful. Outcomes from basic/translational science, 
observational cohorts and clinical trials would then inform subse‐
quent observational cohorts and subsequent biomarker studies 
and clinical trial designs. New subjects can enter these same ob‐
servational cohorts at any time over the course of their lifespan as 
they would be able to contribute to the scientific studies within 
their respective cohorts. The ability to obtain data “snapshots” 
of the status of subjects across all the cohorts/swim lanes would 
allow for reporting the change in inhibitor development and eradi‐
cation over time on a national scale.
4  | IMPLEMENTATION PL AN
Each of the Working Groups provided recommendations on the pri‐
orities for implementation of this national blueprint.5‐8 Next steps in‐
cluded organizational structure and oversight, infrastructure needs, 
funding strategies, as well as training opportunities and needs.
4.1 | Steering committee
Priority should first be given to establishing a Steering Committee 
focused on inhibitor prevention and eradication. This Steering 
Committee should include investigators and representatives from 
the USHTCN, government agencies, database networks, community 
representatives, industry and insurers. Their primary responsibility 
would be to provide oversight for the implementation plan, prioritize 
infrastructure needs, to identify possible funding sources, and to de‐
velop a process for establishing observational cohorts and reviewing 
proposed protocol concepts.
4.2 | Infrastructure needs
A Haemophilia Clinical Trials Group (HCTG) concept was proposed 
from Working Group 15 which would provide the resources for clini‐
cal trial infrastructure. This would facilitate funding for personnel, 
data acquisition, sampling, processing and shipment; set up a single 
IRB for protocol submission; drive trial implementation; and assure 
appropriate clinical trial design and biostatistical support for trial 
concept development.
Working Group 26 highlighted key points for strategic implemen‐
tation that include improvements that build on existing clinical data‐
bases; establishment and optimization of automated clinician‐ and 
patient‐entered data transfer; use of standard measures and PROs 
across studies for harmonization of clinical phenotypes and out‐
comes to facilitate data integration; streamlining of protocols, con‐
tracting and informed consent processes; and centralized tracking of 
biorepository specimens and data.
A recent collaborative research initiative, the NHLBI‐funded 
(U54) Centres for the Investigation of Factor VIII Immunogenicity, 
was launched in 2018.11 These Centres will utilize cross‐disci‐
plinary science and novel technologies to define the basic mech‐
anisms involved in the development of inhibitors to FVIII. Three 
centres have been awarded funding to characterize the functional 
repertoire and ontogeny of FVIII humoral immunity across species 
and to study the in vivo mechanisms of FVIII immunity and the in‐
fluence of the host microbiome. Further, there will be efforts to 
define the structural basis for FVIII immune recognition and related 
immunobiology, to characterize the immunopharmacology of FVIII 
bioengineering and gene therapy to study the role of glycosylation 
in inhibitor formation, and to characterize genetic effects on FVIII 
glycosylation patterns and inhibitor formation. These U54 centres 
will provide insights from basic and translational science that will 
inform the architecture of the clinical research within the obser‐
vational cohorts and interventional trials over the lifespan. The re‐
sults from clinical research will in turn drive new directions in the 
basic and translational science. The novel team science and cross‐
disciplinary infrastructure proposed by Working Group 37 would 
build on these efforts.
The novelty of the antenatal/neonatal observational cohort, as 
proposed by Working Group 4,8 presents new challenges for our 
research infrastructure. They have highlighted the need for new 
systems to recruit carriers and enrol subjects, unique biospecimens 
and real‐time sample acquisition that are suitable to allow for inte‐
gration of ‐omics science and computational biology, as well as the 
need for cross‐disciplinary scientific engagement to explore the role 
of maternal factors and placental biology in contributing to the FVIII 
immune response.
4.3 | Funding strategies
The USHTCN receives federal funding through cooperative grant 
agreements from Health Resources & Services Administration 
and the CDC. However, support for longitudinal cohorts over the 
lifespan will require considerably more resources. The NHLBI has 
recently announced several initiatives that could accelerate imple‐
mentation of the national research blueprint beginning with a re‐
quest for information to solicit input on FVIII immunogenicity and 
FVIII inhibitor prevention/eradication in patients with haemophilia 
A.12 This is an important step in helping NHLBI prioritize funding 
opportunities in the years ahead. NHLBI has also established the 
Innovative Clinical Trials Resource (ICTR) to provide infrastruc‐
ture and expertise to support awardees of the NHLBI “Catalyzing 
Innovation in Late Phase Clinical Trial Design and Statistical 
Analysis Plans Initiative.”13,14 This initiative will provide funding 
support for innovative design and statistical planning for late phase 
(phase II and beyond) single‐site or multi‐site investigator‐initiated 
clinical trials. NHLBI has also announced their intent to publish a 
funding opportunity announcement for rare disease cohorts in 
heart, lung, blood and sleep disorders.15 This planned initiative will 
provide opportunities to efficiently advance rare disease research 
using genetics and deep phenotyping to characterize the disease 
and to identify disease sub‐types and to use data science methods 
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that integrate clinical and patient‐reported outcomes (PROs) with 
laboratory, imaging and ‐omics data to understand the natural his‐
tory of disease. The PhenX Toolkit Inhibitor Standard Measures 
Project,16 sponsored by NHLBI, has proposed standard measures 
for future haemophilia inhibitor research studies to be added to 
the NIH Toolbox17 with a similar project with broader scope within 
haemophilia planned. Public‐private partnerships could also help 
accelerate implementation of the national blueprint. Industry and 
community foundations, including those representing patients, 
could help fund clinical trials, data networks and personnel across 
the haemophilia community to execute the studies that will ulti‐
mately influence the future standard of care for persons with 
haemophilia.
4.4 | Training opportunities and needs
There will be a need to train providers and patients about the best 
strategies for incorporating research with rigorous methodology into 
the HTC culture. To properly study the FVIII immune response as 
proposed by this blueprint would require a commitment to research 
from the first visit, at which persons with haemophilia (PWH) would 
be educated about how they can contribute to research throughout 
their lifespan through a national registry, prospective cohorts, and 
of clinical trials.
Training opportunities would be embedded within clinical tri‐
als. Senior investigators should invite young investigators to par‐
ticipate in NHLBI early phase and late phase single and multi‐site 
clinical trials18‐21 as well as to participate on core committees 
within the HCTG. They would also be embedded in basic and 
translational research programs. As an example, NHLBI U54 cen‐
tres have been structured to include skill development cores that 
will aid in the training of interdisciplinary scientists who can then 
be better equipped to develop future studies on FVIII immunoge‐
nicity and tolerance.11
Additionally, attention would be given to training grants that 
are focused on post‐doctoral cross‐ training in epidemiology, data 
science, clinical trial methodology, immunology, placental biology, 
‐omics, computational biology and haemostasis. These training 
opportunities can leverage NIH National Research Service Award 
(NRSA) and Career Development Award funding mechanisms and 
Physician Scientist Training Programs focused on translational re‐
search in paediatrics, obstetrics and gynaecology and immunology, 
as well as the range of pilot awards currently offered by existing 
foundations, professional societies and industry.22
5  | THE CRUCIAL IMPORTANCE OF 
HAEMOPHILIA COMMUNIT Y ENGAGEMENT
The engagement of the entire haemophilia community is crucial to 
the success of the future national research enterprise. PWH and their 
families are at the core of data and sample collection within this na‐
tional blueprint for inhibitor research over the lifespan. Ideally, the 
perspective of PWH would be sought and considered within all of the 
scientific objectives within this national blueprint. Through improved 
involvement of PWH and their families, clinical trials and protocols 
will be designed to better reflect patient requirements and conducted 
with greater consideration of patient circumstances. This will help de‐
termine which burdens of disease matter most and what aspects of 
clinical trials can be tailored for the PWH/subject. In addition, families 
will better understand the importance of clinical trials and how their 
participation will help improve care for haemophilia.23‐25 PWH have 
a unique perspective and will consider issues differently than regula‐
tors, manufacturers, scientists, clinicians and payers. Thus, this per‐
spective needs to be considered throughout the process of selecting 
outcomes of importance and the development of PRO instruments. 
Feedback of research results directly to patients improves patient 
satisfaction with research, would ensure that PWH have a better un‐
derstanding of the impact of their contribution to research, and likely 
increases the likelihood of future participation in research. Unique 
to this national blueprint for research is the need for identification 
of female carriers to develop the antenatal/birth cohort. This will 
likely require outreach and greater awareness within the community. 
Collaborative efforts with patient organizations such as the National 
Haemophilia Foundation, Haemophilia Federation of America and 
the World Federation of Haemophilia will be a key aspect of patient 
engagement, recruitment and the return of research results.
6  | CONCLUSION
The NHLBI State of the Science Workshop on FVIII Inhibitors was 
a multi‐stakeholder, collaborative initiative that has generated a na‐
tional blueprint for the future of research on FVIII immunogenicity 
with a goal towards the prevention and eradication of inhibitors for 
persons with haemophilia A. The proceedings represented in this 
overview have been archived at the NHLBI.26,27 We wish to thank 
the NHLBI administrative staff, the Working Group Chairs, all the 
Working Group Members, and all of the participants who contrib‐
uted to this work.
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